Paper36545708
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
Xie D and 4 others. Clin Mol Hepatol, 2023. Cited by 166 papers, by iCite.
Cite this record
ConductScience Library. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Papers, record 36545708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36545708
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Male | |
| Sorafenib | |
| Bevacizumab |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82130077 | National Natural Science Foundation of China | PubMed | ||
| 82090053 | National Natural Science Foundation of China | PubMed | ||
| 81961128025 | National Natural Science Foundation of China | PubMed | ||
| 21JC1410100 | Science and Technology Commission of Shanghai Municipality | PubMed | ||
| 21JC1401200 | Science and Technology Commission of Shanghai Municipality | PubMed | ||
| 20JC1418900 | Science and Technology Commission of Shanghai Municipality | PubMed |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 36924120 | The clinical management of hepatocellular carcinoma in China: Progress and challenges. | https://conductscience.org/library/papers/36924120 | PubMed |
| Comment in | 36924123 | Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. | https://conductscience.org/library/papers/36924123 | PubMed |
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12673442 | Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). | J Gastroenterol | 2003 | https://conductscience.org/library/papers/12673442 | PubMed |
| 2 | 35464283 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). | Hepatobiliary Surg Nutr | 2022 | https://conductscience.org/library/papers/35464283 | PubMed |
| 3 | 35978604 | Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. | Liver Cancer | 2022 | https://conductscience.org/library/papers/35978604 | PubMed |
| 4 | 29628281 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. | J Hepatol | 2018 | https://conductscience.org/library/papers/29628281 | PubMed |
| 5 | 33877527 | Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. | Hepatol Int | 2021 | https://conductscience.org/library/papers/33877527 | PubMed |
| 6 | 34143971 | Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34143971 | PubMed |
| 7 | 26146815 | World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. | Hepatology | 2015 | https://conductscience.org/library/papers/26146815 | PubMed |
| 8 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 9 | 22105822 | Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/22105822 | PubMed |
| 10 | 33317248 | Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. | Clin Mol Hepatol | 2021 | https://conductscience.org/library/papers/33317248 | PubMed |
| 11 | 33653656 | Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. | Acad Radiol | 2021 | https://conductscience.org/library/papers/33653656 | PubMed |
| 12 | 19725152 | Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. | World J Gastroenterol | 2009 | https://conductscience.org/library/papers/19725152 | PubMed |
| 13 | 29420221 | Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29420221 | PubMed |
| 14 | 12479938 | Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. | Hepatol Res | 2002 | https://conductscience.org/library/papers/12479938 | PubMed |
| 15 | 34754838 | Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. | J Hepatocell Carcinoma | 2021 | https://conductscience.org/library/papers/34754838 | PubMed |
| 16 | 34185551 | Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34185551 | PubMed |
| 17 | 35284529 | Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study. | Hepatobiliary Surg Nutr | 2022 | https://conductscience.org/library/papers/35284529 | PubMed |
| 18 | 32897657 | Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. | Liver Transpl | 2021 | https://conductscience.org/library/papers/32897657 | PubMed |
| 19 | 29624699 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. | Hepatology | 2018 | https://conductscience.org/library/papers/29624699 | PubMed |
| 20 | 29995681 | Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. | Ann Surg | 2020 | https://conductscience.org/library/papers/29995681 | PubMed |
Cited by131
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967027 | Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42967027 | PubMed |
| 42958661 | Xiaoyao San enhances the sensitivity of hepatocellular carcinoma to 5-fluorouracilautophagy modulation. | J Tradit Chin Med | 2026 | https://conductscience.org/library/papers/42958661 | PubMed |
| 42927357 | Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42927357 | PubMed |
| 42893081 | Construction of a Nomogram Integrating Magnetic Resonance Imaging Features and Ephrin-A3 Expression to Predict Postoperative Overall Survival in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42893081 | PubMed |
| 42724514 | Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724514 | PubMed |
| 42592511 | A gradient core-shell microsphere to enable effective embolization of liver cancer via interventional therapy. | Regen Biomater | 2026 | https://conductscience.org/library/papers/42592511 | PubMed |
| 42588737 | The Controlling Nutritional Status Score as a Predictive Factor for Lung Metastasis in Patients with Hepatocellular Carcinoma After Hepatectomy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588737 | PubMed |
| 42564342 | Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42564342 | PubMed |
| 42542804 | HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42542804 | PubMed |
| 42540626 | Apatinib resistance mediated by IRF9 nuclear translocation in head and neck squamous cell carcinoma. | iScience | 2026 | https://conductscience.org/library/papers/42540626 | PubMed |
| 42445440 | The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42445440 | PubMed |
| 42440203 | Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression. | Saudi Pharm J | 2026 | https://conductscience.org/library/papers/42440203 | PubMed |
| 42433265 | Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42433265 | PubMed |
| 42373443 | [Transitional and clinical practice pathways for whole-course management of hepatocellular carcinoma in the infectious diseases department]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42373443 | PubMed |
| 42358545 | AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab. | Front Oncol | 2026 | https://conductscience.org/library/papers/42358545 | PubMed |
| 42326932 | Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma. | Front Public Health | 2026 | https://conductscience.org/library/papers/42326932 | PubMed |
| 42304258 | MRI radiomics and 90Y PET dosimetry for predicting hepatocellular carcinoma response after radioembolization. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42304258 | PubMed |
| 42301580 | TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis. | Eur Radiol Exp | 2026 | https://conductscience.org/library/papers/42301580 | PubMed |
| 42292386 | Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292386 | PubMed |
| 42270819 | Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42270819 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE | 1636 | PubTator's text mining | https://conductscience.org/library/genes/1636 | NCBI Gene |
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36545708
GET https://conductscience.org/api/papers/v1/36545708/references?page=2